APRIL 21-24, 2020

VIRTUAL

Press Releases

Arrowhead Publishers Announces the Preliminary Speaker Faculty for 6th Annual Translational Microbiome Conference

November 7, 2019 – Minneapolis, MN – Arrowhead Publishers has announced the preliminary speaking faculty for the 6th Annual Translational Microbiome Conference. This conference, taking place April 21-23, 2020 in Boston, MA, will once again bring together the top researchers, leaders, companies and institutions in the field of microbiome science to share novel research, discuss issues relating to the commercialization of microbiome-based products and share new findings relating to the microbiome that are relevant for healthcare providers

This year’s conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome industry will have to recognize and navigate in order to successfully commercialize their products.

Key subject covered include:

• Research standards
• Manufacturing challenges
• Funding issues and challenges
• Therapeutic interventions undergoing clinical trials
• Novel microbiome science
• Gut-brain axis
• Microbiome sampling and diagnostics

For more information on the conference, visit www.microbiomeconference.com.

Speakers Include:
• Rachel Clemens, Ph.D., Commercial Innovation Manager, Life Science Lead, ISS US National Lab, Center for Advancement in Science in Space
• Lynne Elmore, Ph.D., Director, Translational Cancer Research Program, American Cancer Society
• Garth Ehrlich, Ph.D., Professor of Microbiology & Immunology, Professor of Otolaryngology - Head and Neck Surgery, Drexel University College of Medicine
• Wendy Garrett, Ph.D., Professor of Immunology and Infectious Diseases, Department of Immunology and Infectious Diseases, Department of Genetics and Complex Diseases, Department of Medicine, Harvard Medical School
• Momo Vuyisch, Ph.D., Chief Scientific Officer, Viome
• Shahram Lavasani, Ph.D., Founder, CEO/CSO, Immune Biotech
• Scott Jackson, Ph.D., Group Leader, Complex Microbial Systems, NIST
• Nancy Caralla, Founding President, Executive Director, C Diff Foundation
• Rachel Teitelbaum, Ph.D., Chief Executive Officer, Hervana
• Sonia Timberlake, Ph.D., Vice President of Research, Finch Therapeutics
• Dae-Wook Kang, Ph.D., Assistant Professor, Department of Civil & Environmental Engineering, University of Toledo
• Sameer Sonkusale, Ph.D., Professor of Electrical and Computer Engineering, Professor of Biomedical Engineering (adjunct), Director/Principal Investigator, Nano Lab, Tufts University
• Amy Feehan, Ph.D., Research Scientist, Ochsner Health System
• Ze'ev Ronai, Ph.D., Professor, Sanford Burnham Prebys Medical Discovery Institute
• Sangeeta Khare, Ph.D., Research Microbiologist, National Center for Toxicological Research, US Food and Drug Administration
• Lionel Breton, Ph.D., DSc, Scientific Director, L'Oreal Advanced Research, L'Oreal
• Anandh Babu Pon Velayutham, Ph.D., Associate Professor, Nutrition and Integrative Physiology, University of Utah
• Sara Ferrando Martinez, Ph.D., Research Scientist, AstraZeneca
• Julius Goepp, MD, Chief Executive Officer, Scaled Microbiomics
• Stewart Campbell, Ph.D., Vice President, Early Stage Development, Axial Biotherapeutics
• Gregg Silverman, MD, Professor of Medicine and Pathology, New York University School of Medicine
• Henri Haiser, Ph.D., Associate Scientific Director, GI Drug Discovery, Microbiome Sciences, Takeda
• Steve Schnittger, VP Global Microbiology R&D, Estee Lauder
• Mahmoud Ghannoum, Ph.D., EMBA, Professor, Department of Dermatology, Case Western Reserve University and University Hospitals Cleveland Medical Center

For the full list of speakers, CLICK HERE.


For more information, please contact:
John Waslif: Conference Director
Arrowhead Publishers
866-945-0263 ext 700
This email address is being protected from spambots. You need JavaScript enabled to view it.

Consumer track focuses on challenges and progress insights for companies creating microbiome-based consumer products and services

MINNEAPOLIS, March 6, 2018– Arrowhead Publishers released a parallel consumer track agenda for the 4th Annual Translational Microbiome Conference, April 18-20 in Boston. The conference is designed to bring together scientists at the forefront of microbiome research with pioneering business leaders at companies innovating microbiome-based medical solutions. The consumer track focuses on issues and learnings around direct-to-consumer product and service development, with an eye toward helping companies successfully (and efficiently) navigate from research and product innovation through regulation, commercialization and marketing.

“Microbiome research is delivering medical advancements across oncology, dermatology, inflammatory disorders, mental health and many related fields,” said John Waslif, Managing Director of Arrowhead Publishers. “The consumer track at our 4th Annual Translational Microbiome Conference provides a forum for companies to share best practices and process solutions. People want to take control of their health with access to the same science that’s making headlines in leading hospitals and medical labs, and we want to help speed the path to commercialization.”
As recent discoveries illustrate the many essential roles the human microbiome plays within the human ecosystem, scientists are discovering specific variables within the microbiome can profoundly impact a variety of conditions and diseases. To support exploration of translational consumer applications, consumer track presentations and discussion topics are broadly applicable, spanning multiple disease states and addressing issues common to companies in this space.


Consumer track sessions include:
Probiotic Hygiene and Care Response
Robin Temmerman, Ph.D., Chief Executive Officer, Chrisal, N.V.
Resistance of microbes to antibiotics and disinfectants is growing quickly, and allergies to chemical ingredients in cleaning and personal care products are on the rise. Rapid evolution in microbiological research has led to promising new probiotic hygiene technologies in the form of cleaning and personal care applications. For the past 15 years, Chrisal has invested to develop product solutions to widespread hygiene problems like biofilm, smell and infections. Dr. Temmerman will discuss the technology, mechanisms and benefits of probiotic hygiene and care.

Probiotic Home: The Future of Clean
John Howell, Industry Technology Specialist HHC, Novozymes
Consumers are increasingly aware of the microbiota surrounding them, and its integral role in their healthy lifestyle. They may not yet think of microbiota as a solution to what they spill on the floor. Yet, microorganisms, or probiotics, are nature’s oldest and most reliable cleaning crew. They work overtime to break down organics, for a deeper and longer-lasting “probiotic clean” than conventional chemicals. While the technology has long been used industrially, this concept has just recently started to resonate with consumers for application in their home environment. Mr. Howell will share several industrial and domestic cleaning scenarios in which microorganism-containing products are currently used, and he’ll predict future consumer cleaning habits and products that will selectively reinforce the microbiome of the home.

Panel Session: The Future of Probiotic Hygiene
Moderated by Joe Rubino, R&D Director for Reckitt Benckiser, panelists will include Matt Franken, Chief Executive Officer of Aunt Fannies; Robin Temmerman, Ph.D., Chief Executive Officer of Chrisal N.V. and other industry experts.

Early Life Microbiome: Connections between Nutritional Composition, Gastrointestinal Tract and the Brain
Maciej Chichlowski, Ph.D., PMP, Principal Scientist, Mead Johnson Nutrition (RB)
Optimal development of the microbiome is an emerging health benefit that’s likely to grow in consumer awareness and demand over time. Intestinal microbiota plays a role in metabolic, nutritional, physiological and immunological processes in the human body, and nutrition can affect gut microbiota colonization. Our research demonstrates that functional properties of early nutrition could benefit the microbiome and health. For instance, our studies have shown that early life diet with milk fat globule membrane and prebiotics promote immune, gut, and brain development and function.

Using Live Bacteria for Topical Skin Application: Regulatory Issues
Ingmar Claes, Ph.D., Chief Scientific Officer, Yun Probiotherapy
A growing body of data supports the importance of the skin microbiome in its role as a protective barrier against external influence. Products with live beneficial bacteria, or live biotherapeutic products (LBP’s), present the potential to improve symptoms of a multitude of skin disorders. Yet, safety of probiotic strains is of critical importance during the in vitro screening phase. By building up the safety documentation and quality controls in the production of products, Yun Probiotherapy was able to overcome EU regulatory issues and begin marketing their LBP line to consumers.

“Research in the microbiome presents tremendous potential to provide more effective treatments, cures, therapies and supplements,” said Waslif. “As investment opportunities are growing in this area, many companies are rapidly pursuing potential translational solutions. Therefore, sharing key learnings in this space can lend greater efficiency to the development and availability of new pharmaceutical offerings.”

View the full agenda for the 4th Annual Translational Microbiome Conference at www.microbiomeconference.com.
Sponsors and Exhibitors can showcase products and branding in an environment designed to facilitate professional networking. Learn more via www.microbiomeconference.com/sponsor-exhibit.

If you would like more information about this announcement or the 4th Annual Translational Microbiome Conference, please contact John Waslif, Managing Director at Arrowhead Publishers via email at This email address is being protected from spambots. You need JavaScript enabled to view it..

Conference topics will feature speakers and panels on animal models, bioinformatics challenges, intellectual property management, investment deals and approaches, pharma deals in the microbiome space, and the need for standards.

MINNEAPOLIS, November 28, 2017– Arrowhead Publishers unveils a growing roster of speakers for its 4th Annual Translational Microbiome Conference, to take place April 18-20 at Boston Marriott Long Wharf. The conference is designed to connect scientists at the forefront of microbiome research with pioneering companies investing to apply microbiome-based findings to innovate medical solutions. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others) attendees will have the opportunity to hear leading companies discuss the work they have underway and how they are meeting these challenges head-on to apply recent discoveries to a variety of disease processes, restoration of health, and improved outcomes.

“The topics and speakers for this year’s conference offer real education, insights and benefits our attendees can apply within their own organizations,” said John Waslif, Managing Director of Arrowhead Publishers and Conferences.

Speakers already confirmed for the conference include:
Peter Christey, Ph.D.
Co-Founder and Chief Executive Officer, General Automation Lab Technologies (GALT)
GALT’s innovative high-throughput microbiology platform can isolate multiple species from complex samples, such as soil and stool, allowing researchers to rapidly screen whole populations or engineered libraries. Dr. Christey is leveraging GALT tools to revolutionize how microbial studies are conducted, opening previously unreachable territories for scientists to explore.

Olga Danilchanka, Ph.D.
Microbiome Lead, Exploratory Science Center, Merck
Dr. Danilchanka serves as Microbiome Lead for Merck’s Exploratory Science Center, which focuses on the earliest stages of discovery research to better understand the underlying biology of human disease. Dr. Danilchanka’s team explores the most promising areas of emerging disease biology, including the role of the microbiome in disease, and works to gain new insights to inform Merck’s ongoing drug discovery.

Pinaki Panigrahi, M.D., Ph.D.
Professor, Department of Epidemiology and Pediatrics; Director of Center for Global Health and Development, University of Nebraska Medical Center, College of Public Health
An elected fellow of the Infectious Diseases Society of America, Dr. Panigrahi has studied neonatal and child health issues in developed nations and in the developing world. His expertise spans necrotizing enterocolitis, neonatal infections, diarrhea, malaria, birth asphyxia, prematurity, stillbirths and nutrition.

Mark Smith, Ph.D.,
Chief Executive Officer, Finch Therapeutics
Finch uses machine-learning algorithms informed by high-throughput molecular data to reverse-engineer successful clinical experience with fecal transplantation. Rather than relying on in-vitro screening of a library of microbes, Finch uses this human-first discovery approach to identify strains that drive clinical outcomes and to develop therapies that deliver these microbial communities to patients.

Paul Giannasca, Ph.D.
Global Scientific Lead, GI Health, Nestle Health Science
Dr. Giannasca identifies and manages new nutritional and technological platforms relevant for the Gastrointestinal Health strategy for Nestle Health Science. Dr. Giannasca holds multiple U.S. patents covering active and passive immunization against Clostridium difficile disease and has published more than 25 papers in the areas of infectious diseases, vaccine development, active and passive immunization and vaccine-induced protection.

Other notable speakers participating in the 2018 conference include:
* David Kyle, Ph.D., Chief Scientific Officer, Evolve Biosystems
* Ingmar Claes, Ph.D., Chief Scientific Officer, Yun Probiotherapy
* Veronika Oudova, Chief Executive Officer, S Biomedic
* Travis Whitfill, Co-Founder and Chief Science Officer, Azitra
* Jennifer A. Wargo, M.D., Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center

New additions to the conference this year are topic-focused tracks for nutrition and for skin. A parallel consumer track will again be offered. Each track will be closely focused on key issues in its specific industry and the challenges common to companies trying to enter the microbiome space in that area.

Keynote address for the conference will be delivered by Emeran Mayer, M.D., Ph.D.
Director, UCLA Gail and Gerald Oppenheimer Family Center for Neurobiology of Stress; Professor, Medicine; Professor, Psychiatry and Biobehavioral Sciences; Professor, Digestive Diseases/Gastroenterology; Co-Director, CURE: Digestive Diseases Research Center; Professor, Physiology, UCLA David Geffen School of Medicine
Dr. Mayer has a career-long interest in clinical and research aspects of brain-body interactions, with a focus on brain-gut interactions in health and disease. A widely recognized expert for functional GI disorders, he is also recognized as one of the leading investigators in the world of chronic visceral pain and of the brain-gut axis.

Further information about the 4th Annual Translational Microbiome Conference can be found at www.microbiomeconference.com.

Emeran Mayer, World-Renowned Gastroenterologist and Neuroscientist, to Deliver Keynote Address at 4th Annual Translational Microbiome Conference

MINNEAPOLIS, November 16, 2017– Dr. Emeran Mayer will deliver the keynote address at the 4th Annual Translational Microbiome Conference. Dr Mayer is a pioneer in researching brain-body interactions, focusing especially on brain-gut interactions in relation to health and disease. Besides being a widely recognized expert for functional GI disorders, he is also recognized as one of the leading investigators in the world of chronic visceral pain and of the brain-gut axis. Dr. Mayer’s keynote speech is closed to the public but open to registered conference attendees. The conference, which will be hosted by Arrowhead Publishers April 18-20 at the Boston Marriott Long Wharf, provides insight and collaboration opportunities between scientists at the forefront of microbiome research and pioneering companies investing to apply microbiome-based findings to innovate medical solutions.

“Not only is Dr. Mayer a leader in microbiome research,” said John Waslif, Managing Director of Arrowhead Publishers. “His career of investigative research has uncovered such pivotal findings that entire bodies of work are growing from that rich foundation. We are fortunate to hear firsthand about his newest research in April.”

A prolific research author, Dr. Mayer has published 210 original manuscripts in leading GI and Neuroscience journals, and 95 book chapters and reviews, has co-edited three books, and serves as Associate Editor of Gastroenterology. He is director of the Gail and Gerald Oppenheimer Family Center for Neurobiology of Stress. Having served as president of the Functional Brain Gut group, he is also a regular member of the National Institute of Diabetes and Digestive and Kidney Diseases’ Clinical, Integrative and Molecular Gastroenterology study section. Dr. Mayer is currently engaged in research on sex differences in functional GI disorders, brain-bladder interactions, and brain imaging in IBS.

Just as Dr. Mayer’s findings span several medical specialties, his and other recent discoveries illustrate the many essential roles the human microbiome plays within the human ecosystem, and scientists are discovering specific variables within the microbiome that can profoundly impact a variety of conditions and diseases. To align with these findings and support exploration of translational applications, conference topics are broadly applicable, spanning multiple disease states, including oncology and dermatology, as well as inflammatory, cognitive and digestive disorders. In addition to Dr. Mayer’s keynote, progress from other groundbreaking researchers will be shared in conference sessions, and poster board presentations will offer direct access to discuss recent findings and current studies of key interest to the microbiome discussion.

The Translational Microbiome Conference will focus and build upon the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. Research in the microbiome represents tremendous potential to provide more effective therapies and supplements, and as investment opportunities are growing in this area, many companies are rapidly pursuing potential translational work. Sharing key learnings in this space can lend greater efficiency to the development and availability of new pharmaceutical offerings, and sessions will offer insight to how innovative companies are meeting challenges head-on to apply recent discoveries to a variety of disease processes.

Additional speakers for the 2018 Translational Microbiome Conference will be announced soon, and further information about the conference can be found at www.microbiomeconference.com.

Expert Panel Discussions to be Highlight of Agenda at the 3rd Annual Translational Microbiome Conference

Minneapolis, MN – February 15, 2017 – Arrowhead Publishers is pleased to announce that a variety of expert panel discussions have been announced for its upcoming 3rd Annual Translational Microbiome Conference. This event, which will take place April 11-13, 2017 in Boston, MA, will unite presenters and attendees from academia, industry, and the government to provide a multi-stakeholder perspective on the latest trends and developments in the microbiome space. For more information, visit: http://www.microbiomeconference.com.

The CEO of CosmosID Inc. Manoj Dadlani will lead the panel on bioinformatics tools for clinical applications in metagenomics, as well as challenges to overcome in the complex clinical and regulatory environments. Panelists will also discuss the dire need for robust bioinformatics tools that can address the complex clinical and regulatory environments.

Co-founder and CEO of Whole Biome, Dr. Colleen Cultcliffe, will be leading a panel discussion on the microbiome and its growing presence in the media. As new therapeutics are being developed, the microbiome industry must find ways to overcome the hype and unrealistic timelines that can be expected by the general public.

Mohan S. Iyer, CBO at Second Genome, will be moderating the panel on pharma companies working in the microbiome industry. He and the panelists will discuss the latest partnerships between the microbiome industry and pharma, and the deals outlook for 2017.

The “Strategies and Risks for Developing Comprehensive Patent and Licensing Strategies” panel will be led by Greg Sieczkiewicz, Managing Director at MPM Capital. This panel will analyze the various challenges and opportunities that organizations will experience when developing a patent portfolio in the microbiome therapeutics industry. They will also discuss what is necessary from a licensing perspective in order to create a successful pharma-biotech relationship.

Director of Research and Development of Reckitt Benckiser, Joe Rubino, will moderate the panel discussion “Time to Put the Hygiene Hypothesis to Rest?”

JP Benya, Vice President Commercial of Assembly Biosciences will lead the panel discussion on commercial challenges and opportunities in the microbiome-based therapeutics industry. By focusing on critical factors to consider when launching a MBT including regulatory considerations, customer expectations, and messaging implications, this panel will provide expert insight into the future of microbiome-based therapeutics.

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Metagenomics Expert Rita Colwell to Deliver Keynote Address at Arrowhead’s 3rd Annual Translational Microbiome Conference

January 5, 2017 – Minneapolis, MN – The second keynote presentation at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will be given by Dr. Rita Colwell, Distinguished Professor at Johns Hopkins Bloomberg School of Public Health and founder of CosmosID. Her presentation will provide attendees with an overview of the application of metagenomics in improving knowledge of human biology, disease, and the environment. The conference will be taking place April 11-13, 2017 in Boston, MA. For more information, visit: http://www.microbiomeconference.com.

In an era of climate change, high-throughput sequencing and high-resolution bioinformatics are becoming increasingly powerful in microbiome studies, as well as the clinical management of infectious disease and environment. Dr. Colwell will provide several examples of using metagenomics in a clinical setting, including diarrheal disease, waterborne infections, and wastewater reuse.

Founded in 2008 by Dr. Colwell, CosmosID strives to make the world a healthier and safer place by delivering high-resolution bioinformatics for personalized monitoring of environmental bio threat agents in an accurate and cost-effective manner. For more information, visit: http://www.cosmosid.com.

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Thought Leader in Microbiome Research Jack Gilbert to Present at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference

2 December 2016 – Minneapolis, MN – Jack Gilbert, the faculty director of The Microbiome Center and professor at the University of Chicago, has just been announced as the keynote speaker at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference. This conference will once again unite top companies in the microbiome space working to successfully commercialize microbiome-based diagnostics and therapeutics. This conference will be taking place April 11-13, 2017 in Boston, MA. For more information on the conference, visit: http://www.microbiomeconference.com.

As the human microbiome is quickly demonstrating huge roles in the human ecosystem, scientists are discovering that changes in the microbiome have a huge impact on a variety of conditions and diseases. Dr. Gilbert will discuss the latest evidence of these mechanisms of interaction, and how we have started to disturb the delicate balance of immune-microbe equilibrium, thus impacting the development and function of our immune systems. By applying new strategies to identify how the microbial ecosystem correlates with diseases and treatment efficacy through Microbiome-Wide Association Studies (MWAS), microbiome studies are providing a new framework for facilitating patient care.

With an increasing awareness that many of our modern diseases are “lifestyle” related and more than 50% of current medications are ineffective for the people taking them, research in the microbiome presents a potential opportunity to provide more effective treatments, cures, therapies and supplements. Reflective of this trend is the fact that investment opportunities are growing in this area and many companies are rapidly moving towards potential translational work. 

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Continuing Medical Education Credits Now Available for this Event

Joint-Providership Accreditation and Designation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Office of Continuing Medical Education of the University of Virginia School of Medicine and Arrowhead Publishers. The Office of Continuing Medical Education of the University of Virginia School of Medicine is accredited by the ACCME to provide continuing medical education for physicians

The University of Virginia School of Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity. (The number of credits offered for this event is subject to change dependent upon future additions/revisions to the agenda.)

The University of Virginia School of Medicine, as accredited provider, awards 8 hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)TM ) to a participant who successfully completes this educational activity. The University of Virginia School of Medicine maintains a record of participation for six (6) years.

MOC Part II (ABMS) is awarded up to 8 Self-Assessment Credit (transcript awards both MOC and AMA) per learning activity within. Through the American Board of Medical Specialties (ABMS) and Association of American Medical Colleges’ (AAMC) joint initiative to create a wide array of Maintenance of Certification (MOC) Activities. CardioVillage has met the MOC requirements as a MOC Part II CME activity by the following ABMS Member Boards:

MOC Part II CME Activity

  • American Board of Internal Medicine
  • American Board of Pediatrics

Shahram Lavasani, Ph.D.

Founder, Chief Executive Officer and Chief Scientific Officer
Immune Biotech

Shahram Lavasani is an international keynote speaker and entrepreneur in the field of the microbiome. He received his PhD in Immunology from Lund University in Sweden while studying the immunoregulation and immunotherapies in multiple sclerosis (MS). With more than two decades of teaching and research expertise on Gut-Brain axis, he has pioneered research in MS by demonstrating gut inflammation and barrier dysfunction and introduced microbiota-based therapies using probiotic bacterial consortia. He is the founder of ImmuneBiotech developing novel microbiome therapeutics. The company has access to a proprietary lactobacilli library and advanced selection technologies to design nutritional formulations for optimal management of the diseases. ImmuneBiotech´s first product GutMagnificTM has been designed to address the underlying causes of IBS and successfully launched to European market in October 2019.

Scott Jackson, Ph.D.

Group Leader, Complex Microbial Systems
NIST (National Institute of Standards & Technology

In this current role, Scott is leading international efforts to improve microbiome and metagenomic measurements by organizing inter-lab studies, developing reference materials and reference methods, and developing in vitro tools that allow us to better understand microbial community resilience and evolution.

Rachel Clemens, Ph.D.

Commerical Innovation Manager, Life Science Lead
ISS US National Lab, Center for Advancement in Science in Space

Rachel Clemens has focused her career on advancing life science research and product development through experiments in space. In her current role as a Commercial Innovation Manager at the ISS US National Lab, she brings life science research to low earth orbit. She leads partnership development specifically with life science companies – from biotech start-ups to large pharmaceutical companies. She is eager to entertain even the craziest of ideas and passionate about finding novel solutions to Earth-bound problems.

Lynne Elmore, Ph.D.

Director, Translational Cancer Research Program
American Cancer Society

Lynne Elmore, PhD, is the director of the Translational Cancer Research program in the Extramural Grants department of the American Cancer Society (ACS). She manages a research portfolio focused on cell biology, infectious disease, the microbiome, molecular genetics, and cancer drug discovery.

Garth Ehrlich, Ph.D.

Professor of Microbiology & Immunology, Professor of Otolayngology - Head & Neck Surgery
Drexel University College of Medicine

Dr Ehrlich is Professor of Microbiology and Immunology, and Otolaryngology-Head and Neck Surgery at Drexel University College of Medicine (DUCOM) in Philadelphia, PA, USA. Dr. Ehrlich is also the founder and director of three Research Centers of Excellence in the Institute for Molecular Medicine and Infectious Disease: the Center for Genomic Sciences (CGS); the Center for Advanced Microbial Processing (CAMP); and the Center for Surgical Infections and Biofilms.

He also directs Drexel University’s Core Genomics Facility and the Meta-Omics Shared Resource for the Sidney Kimmel Cancer Center – an NCI-designated Cancer Center.

Momo Vuyisich, Ph.D.

Chief Scientific Officer
Viome

Momo Vuyisich is a co-founder and Chief Science Officer at Viome, a data-driven personalized nutrition company. Momo provides scientific leadership at Viome and his vision is to revolutionize healthcare from "symptoms management" to a true preventative medicine. He leads product development, clinical test implementation, and comprehensive clinical research portfolio.

Momo is also an Adjunct Professor at the University of New Mexico and New Mexico Tech. Before co-founding Viome in 2016, Momo spent 12 years at Los Alamos National Laboratory, where he led the Applied Genomics team, which developed the core technology used by Viome today.

Nancy Caralla

Founding President, Executive Director
C Diff Foundation

Nancy C Caralla is a three-time Clostridioides difficile infection (CDI) survivor. She has accumulated over 25 years of experience in the nursing profession blended with over 30 years in international construction management. Over the past several years, Nancy, in partnership with C Diff Foundation members, has focused on raising C. difficile awareness through education and advocating for Clostridium difficile infection prevention, treatments, clinical trials, AMR, and environmental safety worldwide. The C Diff Foundation is a non-profit organization that takes great pride in its volunteers, chairpersons, and committees.

Rachel Teitelbaum, Ph.D.

Chief Executive Officer
Hervana

Rachel Teitelbaum, PhD is the founder and Chief Executive Officer of Hervana Bio Ltd. Dr. Teitelbaum earned her Ph.D. in microbiology and immunology at the Sue Golding Graduate Division of the Albert Einstein College of Medicine. Her academic research career spans more than 15 years, with a focus on research in infectious diseases, in particular relating to the host-pathogen interface, elements of the immune response to intracellular pathogens, the development of animal models of infection and the development of vaccines, in particular for providing effective mucosal immunity. With the founding of Hervana Bio Ltd, Dr. Teitelbaum has applied some of these principles to developing a probiotic therapeutic platform in Women’s Health applications, including the development of a non-hormonal, long-acting biologic contraceptive.

Sonia Timberlake, Ph.D.

Vice President of Research
Finch Therapeutics

Dr. Sonia Timberlake is the VP of Research at Finch Therapeutics, a microbiome therapeutics company. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology.

Dae-Wook Kang, Ph.D.

Assistant Professor, Department of Civil & Environmental Engineering
University of Toledo

Dr. Kang received his BS and MS in Civil and Environmental Engineering from the Seoul National University and his PhD (also in Civil and Environmental Engineering) from the University of Wisconsin-Madison. Prior to joining the University of Toledo in 2019, Dr. Kang was a research scientist in the Biodesign Swette Center for Environmental Biotechnology at the Arizona State University where he was involved in groundbreaking work to establish the relationships between human gut microbiota and autism spectrum disorders. His broad research interests are employing multi-omics technologies and bioinformatics to advance understanding of the role of microbiota on human health, environment, and engineering systems, and eventually to improve human public health and environment sustainability.

Amy Feehan, Ph.D.

Research Scientist
Ochsner Health System

Dr. Feehan is an early stage investigator who received her BS and PhD in Neuroscience from The Brain Institute at Tulane University in New Orleans. She has conducted research in humans and rodents covering topics ranging from drug development of novel endomorphin analogs for pain, to sleep and circadian rhythms research and most recently the gut-brain axis and infectious disease. Her doctoral work led to two patents for a compound that reverses both acute and chronic pain with no observable risk of addiction. She currently works as a research scientist in the Infectious Disease department at Ochsner in New Orleans designing and executing investigator-initiated clinical trials.

Sangeeta Khare, Ph.D.

Research Microbiologist, Division of Microbiology, National Center for Toxicological Research
US Food & Drug Administration

Dr. Sangeeta Khare is a Research Microbiologist in the Division of Microbiology, at National Center for Toxicological Research, Food and Drug Administration. Dr. Sangeeta Khare leads an active team with a research emphasis on host-pathogen and host-microbiome interaction during perturbations with xenobiotic agents (nanoparticles, antibiotics and other drugs, natural products and additives). The main focus of Dr. Khare’s research group is on establishing innovative parameters of host intestinal toxicity.

Julius Goepp, MD

Chief Executive Officer
Scaled Microbiomics

Dr. Goepp is the inventor of “Systems and Methods for Altering Microbiome to Reduce Disease Risk and Manifestations of Disease,” filed as a PCT patent with USPTO on August 27, 2017 and assigned to Scaled Microbiomics, LLC. He has spearheaded the development of Scaled Microbiomics to date, including developing a research team, equipping a laboratory, designing the experiments that produced supporting data on use of IgY in microbiome applications, and interpreting the results.

Ze'ev Ronai, Ph.D.

Professor
Sanford Burnham Prebys Medical Discovery Institute

Ze'ev Ronai obtained his Ph.D. in 1985 from The Hebrew University, Jerusalem Israel and performed his postdoctoral research with I.B. Weinstein at the Cancer Center of Columbia University in New York. He established the Molecular Carcinogenesis Program at the American Health Foundation in Valhalla, New York, and in 1997 moved to the Ruttenberg Cancer Center at Mount Sinai School of Medicine in New York, where he was a tenured professor up to 2005. During 2004, Dr. Ronai moved to Sanford Burnham Prebys Medical Discovery Institute (formerly known as Sanford-Burnham Medical Research Institute) in La Jolla CA, where he is a Professor. He served as the Director of the Signal Transduction Program (2005-2013), as the Deputy Director for the Cancer Center (2008-2014), and as the Scientific Director for the La Jolla site (2014-2016). He established a cancer center at the Technion in Israel (Technion Integrated Cancer Center), while maintaining his activities at SBP (2016-2018). He is currently Chief Scientific Advisor and Professor at Sanford Burnham Prebys Medical Discovery Institute (SBP), La Jolla CA.

Cecile Clavaud, Ph.D.

Project Leader in Skin Microbiome, L'Oreal Advanced Research
L'Oreal

Research and Innovation, France Dr. Clavaud's initial expertise is chemistry and biochemistry to design new radiolabelled probes for medical imaging (Commissariat à l’Energie Atomique, Saclay, FRANCE) followed by four years post doc in the Aspergillus Unit (Institut Pasteur, Paris, FRANCE) to characterize the molecular mechanisms involved in the fungal cell wall polysaccharides biosynthesis. Dr. Clavaud joined L’Oréal Research and Innovation in 2011, to work in an open innovation mode, establishing partnership with international academic experts in the skin and scalp microbiome field. At that stage, she explored the ecology of skin microbiota members (bacteria, fungi and viruses) observed in various skin physio-pathologies and body sites in order to identify key determinants involved in the interaction with skin. Since 2017, she has been involved in building a laboratory dedicated to the skin – microbiota interactions in 3D reconstructed skin models, to better understand how commensal microbiota can impact positively the skin barrier function and the skin quality. Today, she is leading transformation projects turning the recent microbiome knowledge into anti-aging applications.

Anandh Babu Pon Velayutham, Ph.D.

Associate Professor, Department of Nutrition and Inegrative Physiology
University of Utah

Dr. Anandh Babu Pon Velayutham is an Associate Professor in the Department of Nutrition and Integrative Physiology at the University of Utah. His research focuses on identifying novel dietary compounds for the prevention of vascular disease in diabetes and metabolic syndrome. His current research examines the vascular effects of blueberries and strawberries with special emphasis on the microbial metabolites of berry anthocyanins and the molecular signaling mechanisms involved. Dr. Velayutham's research aims to understand the causal association between dietary berries, gut microbiome and vascular health.

Sara Ferrando Martinez, Ph.D.

Research Scientist
AstraZeneca

Dr. Sara Ferrando-Martinez is a Research Scientist at AstraZeneca. Sara is an immunologist that focused on understanding the mechanisms underlying the deterioration of the immune system and how to rejuvenate and recover immune responses as a strategy for immunotherapy. Within AZ Sara is trying to uncover the link between microbiome, microbiome-related products and immune modulation and its impact in health and disease.

A. Stewart Campbell, Ph.D.

VP, Early Stage Development
Axial Biotherapeutics

Dr. Campbell brings more than 25 years of drug discovery and development experience to the team. He has built and led R&D teams involved in a variety of environments from early stage research through to advanced clinical development in small start-ups to mid-sized companies. With capable colleagues he has been fortunate to have triaged several drug candidates from discovery to clinical proof-of-concept in multiple therapeutic areas. He received a Ph.D. in Organic Chemistry from the Queen’s University, which was followed by post-doctoral research at Duke University. He has consulted for several start-up companies in multiple technology and therapeutic areas in the Greater Boston area and is co-inventor on more than 15 issued patents.

Gregg Silverman, MD

Professor of Medicine & Pathology
NYU School of Medicine

Dr. Silverman is Professor of Medicine and Pathology, Associate Director of the Division of Rheumatology, and the Director of the Laboratory of B-cell Immunobiology at the NYU School of Medicine. He is an elected member of AOA, ASCI and the Henry Kunkel Society. After training in Internal Medicine at UCSD, he was a fellow at The Scripps Research Institute in rheumatology and clinical immunology, with a focus on molecular immunology and the structural basis of immune recognition. He has authored over 160 publications and he is on the editorial board of several prestigious journals. Work in his lab is highly translational, with a special interest in B cells and the properties of autoantibodies. and more recently the contributions of the gut microbiome to autoimmune disease.

Mahmoud Ghannoum, Ph.D.

Professor, Department of Dermatology
Case Western University and University Hospitals Cleveland Medical Center

Dr Mahmoud Ghannoum received MSc in Medicinal Chemistry and PhD in Microbial Physiology from University of Technology in England, and an MBA from the Weatherhead School of Management at Case. Presently he is a tenured Professor and Director of the Integrated Microbiome Core and Center for Medical Mycology, Case Western Reserve University and University Hospitals Cleveland Medical Center (UH) where he established a multidisciplinary Center of Excellence that combines basic and translational research investigating medically important fungi from the test tube to the bedside. More recently he pioneered the studies on the fungal communities residing in our body and coined the term ‘Mycobiome”.

He is also a fellow of the Infectious Disease Society of America and past President of the Medical Mycological Society of the Americas (MMSA). In 2016, Dr Ghannoum received the Rohda Benham Award presented for his continuous outstanding and meritorious contributions to medical mycology from the Medical Mycological Society of the Americas and he also received the Freedom to Discover Award from Bristol-Myers Squibb for his work on microbial biofilms. In 2017, he was inducted as a fellow of the American Academy of Microbiology. Beside his academic career Dr. Ghannoum is an entrepreneur-scientist who launched a number of companies focusing on the treatment of biofilm infections as well as microbial dysbiosis as it relates to gut health.

Pamela Silver, Ph.D.

Elliot T. and Onie H. Adams Professor of Biochemistry and Systems Biology
Harvard Medical School

Pamela Silver received her BS in Chemistry and PhD in Biochemistry from the University of California where she was an NIH Pre-doctoral Fellow. She was a Postdoctoral Fellow at Harvard University in the Dept of Biochemistry and Molecular Biology where she was a Fellow of the American Cancer Society and The Medical Foundation. Subsequently, Pam was an Assistant Professor in the Dept of Molecular Biology at Princeton University and then moved to the Dana Farber Cancer Institute where she was a Professor in the Dept of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Pam became one of the founding members of the Department of Systems Biology at Harvard Medical School and the first Director of the Harvard University PhD Program in Systems Biology and one of the first members of the Harvard University Wyss Institute for Biologically Inspired Engineering. Her work has been recognized by an Established Investigator of the American Heart Association, a Research Scholar of the March of Dimes, an NSF Presidential Young Investigator Award, Claudia Adams Barr Investigator, an NIH MERIT award, the Philosophical Society Lecture, a Fellow of the Radcliffe Institute, and election to the American Academy of Arts and Sciences. She is among the top global influencers in Synthetic Biology and her work was named one of the top 10 breakthroughs by the World Economic Forum. She serves on numerous public and private advisory boards including the board of the Internationally Genetics Engineering Machines (iGEM) Competition, and she is the co-founder of several biotech companies.

NEW VIRTUAL EVENT

The 6th Annual Translational Microbiome Conference, scheduled for April 21-23 in Boston, MA has been replaced with a Virtual Conference that will be taking place April 21-24, 2020. Registered attendees will have full access to the ON-DEMAND full broadcast after the event.

REGISTRATION IS NOW OPEN. REGISTER NOW!

The full agenda and timeline is NOW AVAILABLE. CLICK HERE for details.